Prosecution Insights
Prosecution Insights
5 pending office actions • 2 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERSONS, JENNA L | 2 | 50.0% | +60.0% |
| SANKS, SCHYLER S | 1 | 72.7% | +15.9% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.1% | +29.7% |
| MIDDLETON, DANAYA L | 1 | 46.1% | +54.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17777975 | ANTIBODIES TARGETING, AND OTHER MODULATORS OF, THE CD276 ANTIGEN, AND USES THEREOF | MIDDLETON, DANAYA L | 70d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19223597 | CHEMICALLY MODIFIED ANTISENSE OLIGONUCLEOTIDES (ASOS) AND COMPOSITIONS COMPRISING THE SAME FOR RNA EDITING | PERSONS, JENNA L | 8d |
| 17924066 | MODULATION OF MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN SIGNALING | CARTER, SANDRA DILLAHUNT | 70d |
| 17777975 | ANTIBODIES TARGETING, AND OTHER MODULATORS OF, THE CD276 ANTIGEN, AND USES THEREOF | MIDDLETON, DANAYA L | 70d |
| 18578680 | ATOMIC QUANTUM PROCESSOR | SANKS, SCHYLER S | — |
| 18071999 | ANTISENSE OLIGONUCLEOTIDES (ASO) FOR EFFICIENT AND PRECISE RNA EDITING WITH ENDOGENOUS ADENOSINE DEAMINASE ACTING ON RNA (ADAR) | PERSONS, JENNA L | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 1674 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19223597 | CHEMICALLY MODIFIED ANTISENSE OLIGONUCLEOTIDES (ASOS) AND COMPOSITIONS COMPRISING THE SAME FOR RNA EDITING | PERSONS, JENNA L | 1637 | §112 | Non-Final OA | 8d | Pending | May 30, 2025 |
| 18578680 | ATOMIC QUANTUM PROCESSOR | SANKS, SCHYLER S | — | §103 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18071999 | ANTISENSE OLIGONUCLEOTIDES (ASO) FOR EFFICIENT AND PRECISE RNA EDITING WITH ENDOGENOUS ADENOSINE DEAMINASE ACTING ON RNA (ADAR) | PERSONS, JENNA L | 1637 | §103DP | Final Rejection | — | Pending | Nov 30, 2022 |
| 17924066 | MODULATION OF MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN SIGNALING | CARTER, SANDRA DILLAHUNT | 1674 | §112 | Non-Final OA | 70d | Pending | Nov 08, 2022 |
| 17777975 | ANTIBODIES TARGETING, AND OTHER MODULATORS OF, THE CD276 ANTIGEN, AND USES THEREOF | MIDDLETON, DANAYA L | 1674 | §102§112 | Final Rejection | 70d | Pending | May 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial